{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:10Z","timestamp":1790717170847,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1136\/ard.2005.043166","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T01:32:34Z","timestamp":1138325554000},"page":"889-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":311,"title":["Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"65","author":[{"given":"M H","family":"Schiff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Pangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S B","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.043166_bib1","unstructured":"Abbott Laboratories. HUMIRA\u00c2\u00ae (adalimumab). Information available at: www.humira.com (accessed 2 February 2006)."},{"key":"10.1136\/ard.2005.043166_bib2","unstructured":"Wyeth Pharmaceuticals Inc. Enbrel: Etanercept. Information available at: www.enbrel.com (accessed 2 February 2006)."},{"key":"10.1136\/ard.2005.043166_bib3","unstructured":"Centocor, Inc. Remicade: Infliximab. Information available at: www.remicade.com (accessed 2 February 2006)."},{"key":"10.1136\/ard.2005.043166_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib5","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.043166_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.043166_bib7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1136\/ard.2005.043166_bib8","first-page":"P195","article-title":"Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis","volume":"52","author":"Lebwohl","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1136\/ard.2005.043166_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib10","first-page":"11","article-title":"Etanercept \u00e2\u20ac\u201d review of efficacy and safety after five years of clinical use","volume":"1","author":"Fleischmann","year":"2004","journal-title":"Therapy"},{"key":"10.1136\/ard.2005.043166_bib11","first-page":"1232","article-title":"Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.043166_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2005.043166_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rdc.2004.01.003","article-title":"Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments","volume":"30","author":"Bieber","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2005.043166_bib14","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib15","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib16","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib18","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","article-title":"Rheumatoid arthritis and malignant lymphomas","volume":"16","author":"Baecklund","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2005.043166_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"issue":"S65","key":"10.1136\/ard.2005.043166_bib21","first-page":"27","article-title":"Examining the efficacy of biologic therapy: are there real differences?","volume":"29","author":"Fleischmann","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.043166_bib22","unstructured":"Abbott Laboratories. HUMIRA\u00c2\u00ae (adalimumab) [prescribing information]. Abbott Park, IL: Abbott Laboratories, October, 2005."},{"key":"10.1136\/ard.2005.043166_bib23","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.043166_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1136\/ard.2005.043166_bib25","first-page":"S562","article-title":"Global safety in adalimumab (HUMIRA\u00c2\u00ae) rheumatoid arthritis clinical trials","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib26","unstructured":"NCI. Surveillance, Epidemiology and End Results (SEER) Program Public-Use Data (1973\u20131999). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission."},{"key":"10.1136\/ard.2005.043166_bib27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.281.9.824","article-title":"Postmarketing surveillance and adverse drug reactions: current perspectives and future needs","volume":"281","author":"Brewer","year":"1999","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1136\/ard.2005.043166_bib28","first-page":"S242","article-title":"Serious infections in rheumatoid arthritis: relationship to immunosuppressive use","volume":"42","author":"Singh","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.043166_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ard.2005.043166_bib30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1136\/ard.2005.043166_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1136\/ard.2005.043166_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard.2005.043166_bib33","doi-asserted-by":"crossref","first-page":"9203","DOI":"10.1073\/pnas.97.16.9203","article-title":"T cell homeostasis in patients with rheumatoid arthritis","volume":"97","author":"Koetz","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard.2005.043166_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/art1.10243","article-title":"Experience with etanercept in an academic center: are infection rates increased?","volume":"47","author":"Phillips","year":"2002","journal-title":"Arthrits Care Res"},{"issue":"Suppl 1","key":"10.1136\/ard.2005.043166_bib35","first-page":"i11","article-title":"Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR Biologic Register (BSRBR)","volume":"44","author":"Dixon","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2005.043166_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"Suppl","key":"10.1136\/ard.2005.043166_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/rheumatology\/keh617","article-title":"Safety of biologic therapies \u00e2\u20ac\u2022 an update","volume":"32","author":"Keystone","year":"2005","journal-title":"J Rheumatol"},{"issue":"30","key":"10.1136\/ard.2005.043166_bib38","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha \u00e2\u20ac\u201d California, 2002\u20132003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ard.2005.043166_bib39","unstructured":"FDA Briefing Document. Update on the TNF blocking agents. FDA 3\u20134\u20132003. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3930B1_01_B-TNF.Briefing.pdf (accessed 6 February 2006)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724201175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724201175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.043166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:29:36Z","timestamp":1736087376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724201175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0003496724201175"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.043166","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.043166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}